Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

5-HT3 antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalNeurogastroenterology and Motility
Volume19
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Ischemic Colitis
Serotonin 5-HT3 Receptor Antagonists
Irritable Bowel Syndrome
Constipation
Therapeutics
Causality
Vomiting
Blood Vessels
Diarrhea
Epidemiology
Drug Therapy
Pain
Pharmaceutical Preparations

Keywords

  • Alosetron
  • Cilansetron
  • Colon
  • Constipation
  • Ischaemia
  • Mucosa

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

@article{c018094789d34ad183d916e22a4292ac,
title = "Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?",
abstract = "5-HT3 antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.",
keywords = "Alosetron, Cilansetron, Colon, Constipation, Ischaemia, Mucosa",
author = "Michael Camilleri",
year = "2007",
month = "2",
doi = "10.1111/j.1365-2982.2006.00861.x",
language = "English (US)",
volume = "19",
pages = "77--84",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

AU - Camilleri, Michael

PY - 2007/2

Y1 - 2007/2

N2 - 5-HT3 antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.

AB - 5-HT3 antagonists are effective treatments for chemotherapy-induced emesis and diarrhoea and urgency and pain associated with irritable bowel syndrome. Reports of ischaemic colitis led to restricted use of the approved drug, alosetron. This article briefly reviews the controversial information from epidemiology and adverse reaction reports and addresses the experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment. The author reviews the potential factors based involved in the ischaemic colitis and ways in which this class of compound may influence those factors based on experimental evidence, including the literature on any vascular effects of these agents. Finally, the article addresses the theoretical basis for the constipation as a predisposing factor for the development of ischaemic colitis. The evidence reviewed suggests that further studies are needed to explore the principles to prove or disprove the association.

KW - Alosetron

KW - Cilansetron

KW - Colon

KW - Constipation

KW - Ischaemia

KW - Mucosa

UR - http://www.scopus.com/inward/record.url?scp=33846348301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846348301&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2006.00861.x

DO - 10.1111/j.1365-2982.2006.00861.x

M3 - Article

C2 - 17244161

AN - SCOPUS:33846348301

VL - 19

SP - 77

EP - 84

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 2

ER -